Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956357 | 0.88 | POLB (0.39) | POLBTSHRMALT1DRD2GAA | |
| SCHEMBL4717209 | 0.83 | MALT1 (0.43) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL4612508 | 0.83 | MALT1 (0.43) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL4719257 | 0.81 | MALT1 (0.41) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL951564 | 0.79 | POLB (0.40) | POLBTSHRGAAKMT2AALDH1A1 | |
| SCHEMBL4599868 | 0.78 | KMT2A (0.47) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL1637220 | 0.78 | KMT2A (0.47) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL4600039 | 0.78 | KMT2A (0.47) | MALT1DRD2KCNA5GAAKMT2A | |
| SCHEMBL4599808 | 0.77 | TPSAB1 (0.44) | MALT1DRD2GAAKMT2AALDH1A1 | |
| SCHEMBL4600306 | 0.77 | TPSAB1 (0.44) | MALT1DRD2GAAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362236-B2 | Macrocyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-2119718-B1 | MACROCYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | POLB 3420/4885TSHR 1878/4885MALT1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.